| Elizabeth Ann Friske, OTR,CHT | |
|
112 E 5th Ave, Antigo, WI 54409-2710 | |
| (715) 623-9449 | |
| (715) 623-9425 |
| Full Name | Elizabeth Ann Friske |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapy |
| Experience | 34 Years |
| Location | 112 E 5th Ave, Antigo, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003940727 | NPI | - | NPPES |
| 40722700 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225XH1200X | Occupational Therapist - Hand | 1544-026 (Wisconsin) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mchs Hospitals Inc | 5698071173 | 1049 |
News Archive
Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, today announced that the U.S. Food and Drug Administration (FDA) has granted 510K marketing clearance of the new C-Reactive Protein (CRP) assay when used by healthcare professionals in conjunction with the Piccolo Xpress™ point-of-care analyzer.
Enzon Pharmaceuticals, Inc. today announced the results from the recent tender and increased conversion periods of the 4 percent convertible notes due in 2013. As a result of the sale of the specialty pharmaceutical business on January 29, 2010, the Company was required to offer to repurchase for cash any and all of its convertible notes at face value. This offer expired on March 5, 2010 and no notes were tendered.
Regular use of aspirin may help slow the progression of early emphysema, according to new research presented at the 2015 American Thoracic Society International Conference.
New evidence indicates that cutting back on state-sponsored smoking prevention campaigns could result in a sharp increase in smoking rates, particularly among adolescents, and should convince all states to protect these programs, according to the American Heart Association.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) on November 18, 2011 to remove the pre-treatment biodistribution evaluation requirement using Indium-111 ZEVALIN imaging dose followed by a gamma scan before administering the ZEVALIN therapeutic dose.
› Verified 6 days ago
| Provider Name | Marshfield Clinic Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1952347981 PECOS PAC ID: 2264345206 Enrollment ID: O20031106000590 |
News Archive
Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, today announced that the U.S. Food and Drug Administration (FDA) has granted 510K marketing clearance of the new C-Reactive Protein (CRP) assay when used by healthcare professionals in conjunction with the Piccolo Xpress™ point-of-care analyzer.
Enzon Pharmaceuticals, Inc. today announced the results from the recent tender and increased conversion periods of the 4 percent convertible notes due in 2013. As a result of the sale of the specialty pharmaceutical business on January 29, 2010, the Company was required to offer to repurchase for cash any and all of its convertible notes at face value. This offer expired on March 5, 2010 and no notes were tendered.
Regular use of aspirin may help slow the progression of early emphysema, according to new research presented at the 2015 American Thoracic Society International Conference.
New evidence indicates that cutting back on state-sponsored smoking prevention campaigns could result in a sharp increase in smoking rates, particularly among adolescents, and should convince all states to protect these programs, according to the American Heart Association.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) on November 18, 2011 to remove the pre-treatment biodistribution evaluation requirement using Indium-111 ZEVALIN imaging dose followed by a gamma scan before administering the ZEVALIN therapeutic dose.
› Verified 6 days ago
| Provider Name | Mchs Hospitals Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1093221434 PECOS PAC ID: 5698071173 Enrollment ID: O20180208000096 |
News Archive
Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, today announced that the U.S. Food and Drug Administration (FDA) has granted 510K marketing clearance of the new C-Reactive Protein (CRP) assay when used by healthcare professionals in conjunction with the Piccolo Xpress™ point-of-care analyzer.
Enzon Pharmaceuticals, Inc. today announced the results from the recent tender and increased conversion periods of the 4 percent convertible notes due in 2013. As a result of the sale of the specialty pharmaceutical business on January 29, 2010, the Company was required to offer to repurchase for cash any and all of its convertible notes at face value. This offer expired on March 5, 2010 and no notes were tendered.
Regular use of aspirin may help slow the progression of early emphysema, according to new research presented at the 2015 American Thoracic Society International Conference.
New evidence indicates that cutting back on state-sponsored smoking prevention campaigns could result in a sharp increase in smoking rates, particularly among adolescents, and should convince all states to protect these programs, according to the American Heart Association.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) on November 18, 2011 to remove the pre-treatment biodistribution evaluation requirement using Indium-111 ZEVALIN imaging dose followed by a gamma scan before administering the ZEVALIN therapeutic dose.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth Ann Friske, OTR,CHT N2998 County Road K, Merrill, WI 54452-9413 Ph: (715) 536-1963 | Elizabeth Ann Friske, OTR,CHT 112 E 5th Ave, Antigo, WI 54409-2710 Ph: (715) 623-9449 |
News Archive
Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, today announced that the U.S. Food and Drug Administration (FDA) has granted 510K marketing clearance of the new C-Reactive Protein (CRP) assay when used by healthcare professionals in conjunction with the Piccolo Xpress™ point-of-care analyzer.
Enzon Pharmaceuticals, Inc. today announced the results from the recent tender and increased conversion periods of the 4 percent convertible notes due in 2013. As a result of the sale of the specialty pharmaceutical business on January 29, 2010, the Company was required to offer to repurchase for cash any and all of its convertible notes at face value. This offer expired on March 5, 2010 and no notes were tendered.
Regular use of aspirin may help slow the progression of early emphysema, according to new research presented at the 2015 American Thoracic Society International Conference.
New evidence indicates that cutting back on state-sponsored smoking prevention campaigns could result in a sharp increase in smoking rates, particularly among adolescents, and should convince all states to protect these programs, according to the American Heart Association.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) on November 18, 2011 to remove the pre-treatment biodistribution evaluation requirement using Indium-111 ZEVALIN imaging dose followed by a gamma scan before administering the ZEVALIN therapeutic dose.
› Verified 6 days ago
Katelyn Williams-parilek, MS, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 112 E 5th Ave, Antigo, WI 54409 Phone: 715-623-9449 | |
Mrs. Amy Michelle Zanayed, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 112 E 5th Ave, Antigo, WI 54409 Phone: 715-623-2331 | |
Mark G Buchman, MS, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 112 E 5th Ave, Antigo, WI 54409 Phone: 715-623-9449 Fax: 715-623-9425 | |
Rand Chubin, Occupational Therapist Medicare: Medicare Enrolled Practice Location: 729 Park St, Antigo, WI 54409 Phone: 715-623-2356 Fax: 715-623-6653 | |
Mary R Brayton, MS, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 112 E 5th Ave, Antigo, WI 54409 Phone: 715-623-9469 | |
Michelle A Klingler, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 729 Park St, Antigo, WI 54409 Phone: 715-623-2356 |